310 related articles for article (PubMed ID: 28028994)
1. An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016).
Lee SW; Kim YM; Kim YT; Kang SB
J Gynecol Oncol; 2017 May; 28(3):e26. PubMed ID: 28028994
[TBL] [Abstract][Full Text] [Related]
2. An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021).
Lee SW; Kim YM; Cho CH; Kim YT; Kim SM; Hur SY; Kim JH; Kim BG; Kim SC; Ryu HS; Kang SB
Cancer Res Treat; 2018 Jan; 50(1):195-203. PubMed ID: 28324920
[TBL] [Abstract][Full Text] [Related]
3. Safety and Tolerability of Weekly Genexol-PM, a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel, with Carboplatin in Gynecologic Cancer: A Phase I Study.
Nam SH; Lee SW; Lee YJ; Kim YM
Cancer Res Treat; 2023 Oct; 55(4):1346-1354. PubMed ID: 37189263
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.
Kim TY; Kim DW; Chung JY; Shin SG; Kim SC; Heo DS; Kim NK; Bang YJ
Clin Cancer Res; 2004 Jun; 10(11):3708-16. PubMed ID: 15173077
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of paclitaxel and carboplatin with a biweekly schedule in patients with epithelial ovarian cancer: Gynecologic Cancer Network trial.
Yoneyama K; Konishi H; Yahata T; Fujita K; Aoki Y; Doi D; Matsushima T; Kodama S; Honma S; Kato H; Nakayama H; Kamoi S; Asakura H; Takeshita T; Tanaka K
J Nippon Med Sch; 2014; 81(1):28-34. PubMed ID: 24614392
[TBL] [Abstract][Full Text] [Related]
7. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Katsumata N; Yasuda M; Isonishi S; Takahashi F; Michimae H; Kimura E; Aoki D; Jobo T; Kodama S; Terauchi F; Sugiyama T; Ochiai K;
Lancet Oncol; 2013 Sep; 14(10):1020-6. PubMed ID: 23948349
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
Gordon AN; Hancock KC; Matthews CM; Messing M; Stringer CA; Doherty MG; Teneriello M
Gynecol Oncol; 2002 Apr; 85(1):129-35. PubMed ID: 11925132
[TBL] [Abstract][Full Text] [Related]
12. An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer.
Park IH; Sohn JH; Kim SB; Lee KS; Chung JS; Lee SH; Kim TY; Jung KH; Cho EK; Kim YS; Song HS; Seo JH; Ryoo HM; Lee SA; Yoon SY; Kim CS; Kim YT; Kim SY; Jin MR; Ro J
Cancer Res Treat; 2017 Jul; 49(3):569-577. PubMed ID: 27618821
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
Lee JL; Ahn JH; Park SH; Lim HY; Kwon JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Invest New Drugs; 2012 Oct; 30(5):1984-90. PubMed ID: 22012004
[TBL] [Abstract][Full Text] [Related]
14. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
Meerpohl HG; du Bois A; Kühnle H; Lück HJ; Kreienberg R; Möbus V; Bauknecht T; Köchli O; Bochtler H; Diergarten K
Semin Oncol; 1995 Dec; 22(6 Suppl 15):7-12. PubMed ID: 8643973
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies.
Shi M; Sun J; Zhou J; Yu H; Yu S; Xia G; Wang L; Teng Y; Liu G; Yu C; Feng J; Shen Y
Invest New Drugs; 2018 Apr; 36(2):269-277. PubMed ID: 28868573
[TBL] [Abstract][Full Text] [Related]
18. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy.
Kim SC; Kim DW; Shim YH; Bang JS; Oh HS; Wan Kim S; Seo MH
J Control Release; 2001 May; 72(1-3):191-202. PubMed ID: 11389998
[TBL] [Abstract][Full Text] [Related]
19. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gould N; Sill MW; Mannel RS; Thaker PH; Disilvestro P; Waggoner S; Yamada SD; Armstrong DK; Wenzel L; Huang H; Fracasso PM; Walker JL
Gynecol Oncol; 2012 Apr; 125(1):54-8. PubMed ID: 22155262
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer.
Kim DW; Kim SY; Kim HK; Kim SW; Shin SW; Kim JS; Park K; Lee MY; Heo DS
Ann Oncol; 2007 Dec; 18(12):2009-14. PubMed ID: 17785767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]